drugset / Trial / NCT00484874
Safety and Efficacy Study of I-131 Tositumomab in Patients With Relapsed/Refractory Hodgkin's Lymphoma
Phase 1/2
Completed
12 enrolled
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
GlaxoSmithKline · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to find the highest safe dose of Iodine-131 Tositumomab (Bexxar®) that can be given to patients who have relapsed/refractory Hodgkin's lymphoma, what side effects these patients get when they take Bexxar® and if Bexxar® is effective in treating relapsed/refractory Hodgkin's lymphoma. Bexxar® works by delivering doses of radiation to cancer cells.
Timeline
- Start
- 2007-06
- Primary completion
- 2014-01
- Completion
- 2015-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TOSITUMOMAB 131I | Monoclonal antibody | — | Intravenous |